培美曲塞单药治疗复治进展期非小细胞肺癌的临床观察

Clinical observation of pemetrexed in treatment of advanced retreated non-small cell lung cancer

为了观察培美曲塞单药治疗复治进展期非小细胞肺癌(NSCLC)患者的临床疗效和毒副反应,对22例复治进展期NSCLC患者采用培美曲塞单药化疗,所有病例均有可测量和评价病灶。培美曲塞500mg/m2,静脉滴入,d1,21d为1个周期,连用2～6个周期,进行评价疗效。全组22例均可评价疗效,其中CR0例,PR2例,客观有效率(RR)9.09%。临床获益率(CR+PR+SD)45.45%,中位疾病进展时间3.2个月,中位生存期7.3个月,主要毒副反应为骨髓抑制、胃肠道毒性。初步研究结果提示,培美曲塞单药治疗复治进展期NSCLC疗效确切,不良反应小,值得临床推广。

The objective of this study was to observe the effects and toxicities of pemetrexed in the treatment of patients with advanced retreated non-small cell lung cancer. Twenty two patients with advanced retreated non-small cell lung cancer diagnosed by pathology or cytology were enrolled into the study. The patients received pemetrexed 500 mg/m^2 on dl. The cycles were repeated every 21 days. All the patients were evaluated after 2-6 cycles of the chemotherapy. The overall response rate was 9.09% （including 0 CR, 2 PR）, and the clinical benefit rate was 45.45%. The median time to tumer （TTP） was 3.2 months and the median overall survival （OS） was 7.3 months. The common adverse effects were hone marrow suppression and gastrointestinal toxicity. In conclusion, pemetrexed is active and well tolerated in the treatment of patients with advanced retreated NSCLC.